This site is intended for U.S. health care professionals only.

Ordering Information

Orbactiv® (oritavancin) for injection vial
Three single use
vials = 1200 mg dose
Orbactiv® (oritavancin) 400mg per vial
Carton: NDC 65293-015-03
How Supplied

Three ORBACTIV® vials are packaged in a carton to supply for a single 1200 mg dose treatment.

ORBACTIV® is supplied as sterile, white to off-white lyophilized powder equivalent to 400 mg of oritavancin in a single use 50 mL clear glass vial.

Weight Carton
0.22 lb/100 g
Dimensions Carton
5.125 x 2.125 x 3 in (LxWxH)

ORBACTIV® vials should be stored at 20ºC to 25ºC (68ºF to 77ºF); excursions permitted to 15ºC to 30ºC (59ºF to 86ºF).


ORBACTIV® is a wholesaler stocked product. Please use standard ordering procedure through your wholesaler. If product is not available at your wholesaler, your wholesaler can easily coordinate a drop shipment via Next Day Saver from MDCO primary distribution provider.

To download the Order Sheet, please click the PDF
link below.

Orbactiv® (oritavancin) for injection order sheet

Important Safety Information


Use of intravenous unfractionated heparin sodium is contraindicated for 120 hours (5 days) after ORBACTIV® administration because the activated partial thromboplastin time (aPTT) test results are expected to remain falsely elevated for approximately 120 hours (5 days) after ORBACTIV® administration.

ORBACTIV® is contraindicated in patients with known hypersensitivity to ORBACTIV®.

Warnings and Precautions

Coagulation test interference: ORBACTIV® has been shown to artificially prolong aPTT for up to 120 hours, and may prolong PT and INR for up to 12 hours, ACT for up to 24 hours, and D-dimer for up to 72 hours.

Hypersensitivity reactions have been reported with the use of antibacterial agents including ORBACTIV®. Discontinue infusion if signs of acute hypersensitivity occur. Monitor closely patients with known hypersensitivity to glycopeptides.

Infusion-related reactions have been reported. Slow the rate or interrupt infusion if infusion reaction develops.

Clostridium difficile-associated colitis: Evaluate patients if diarrhea occurs.

Concomitant warfarin use: Patients should be monitored for bleeding if concomitantly receiving ORBACTIV® and warfarin.

Osteomyelitis: Institute appropriate alternate antibacterial therapy in patients with confirmed or suspected osteomyelitis.

Prescribing ORBACTIV® in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of development of drug-resistant bacteria.

Adverse Reactions

The most common adverse reactions (≥3%) in patients treated with ORBACTIV® were headache, nausea, vomiting, limb and subcutaneous abscesses, and diarrhea.

See Full Prescribing Information

This site is intended for U.S. Healthcare Professionals. If you are a U.S. Healthcare Professional, click OK to continue.